BioSpace - Targacept, Inc. News, Search Jobs, Events

BioSpace Login

Enter your BioSpace account email address and password to log in now.

Email Address

Password

Keep me logged in

Close Window

Forgot Your Password? | Privacy Statement

NEW MEMBER SIGN UP

Display Name

Email Address

Password

Password again

Zip

Country

Close Window

Privacy Statement

BioSpace.com

Biotech and Pharmaceutical
News & Jobs

Search the Site

Community Login

What is this?

Employers
Post Job | Search Resumes | Login

NEWSLETTERS
Free Newsletters
Archive
My eNewsletters

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

COMMUNITY
Login
Become a Member
Discussion Forums
FAQ

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile

Targacept, Inc.

200 East First Street
Suite 300
Winston-Salem North Carolina 27101-4165 U.S.A.
Phone: 336-480-2100 Fax: 336-480-2107

Targacept, Inc. is a clinical-stage biopharmaceutical company that discovers and develops NNR Therapeutics™, a new class of drugs for the treatment of central nervous system diseases and disorders, in support of its vision of building health and restoring independence for patients. Targacept’s product candidates selectively modulate neuronal nicotinic receptors that serve as key regulators of the nervous system to promote therapeutic effects and limit adverse side effects. Targacept has clinical-stage product candidates in development for major depressive disorder, attention deficit/hyperactivity disorder, Alzheimer’s disease and cognitive dysfunction in schizophrenia, as well as multiple preclinical programs. Targacept recently announced a global collaboration and license agreement with AstraZeneca for the late-stage investigational product TC-5214 for the treatment of major depressive disorder. Targacept also has a cognition-focused collaboration with AstraZeneca and a strategic alliance with GlaxoSmithKline.

Targacept’s news releases are available on its website at www.targacept.com.

Key Statistics

Email: jo.peay@targacept.com
Ownership:
Web Site: Targacept, Inc.
Employees: 115
Symbol: TRGT

Industry
Biopharmaceutical

Company News

Targacept, Inc. (TRGT) Awarded a Grant from The Michael J. Fox Foundation to Conduct Biomarker Research for Parkinson’s Disease 2/8/2010 8:50:51 AM More...

Targacept, Inc. (TRGT) to Report Fourth Quarter and 2009 Financial Results on February 11, 2010 2/4/2010 11:03:51 AM More...

Targacept, Inc. (TRGT) to Present at Biotechnology Industry Organization (BIO) CEO & Investor Conference 2/2/2010 11:21:04 AM More...

Targacept, Inc. (TRGT) Receives $200 Million Upfront Payment from AstraZeneca PLC (AZN) (JOBS) 1/11/2010 8:14:24 AM More...

Targacept, Inc. (TRGT) Initiates Phase 2 Study of TC-5619 in Cognitive Dysfunction in Schizophrenia 12/10/2009 8:49:20 AM More...

Targacept, Inc. (TRGT) to Host Conference Call Today at 10:00 AM to discuss AstraZeneca PLC (AZN) Collaboration on TC-5214 for Major Depressive Disorder 12/3/2009 9:41:52 AM More...

AstraZeneca PLC (AZN) (JOBS) to Pay Up to $1.24 Billion for Targacept, Inc. (TRGT) Drug 12/3/2009 6:40:40 AM More...

Targacept, Inc. (TRGT) Added to NASDAQ Biotechnology Index 11/16/2009 10:35:10 AM More...

Targacept, Inc. (TRGT) to Present at the Lazard Capital Markets 6th Annual Healthcare Conference 11/11/2009 8:38:28 AM More...

Targacept, Inc. (TRGT) Reports Third Quarter 2009 Financial Results 11/6/2009 9:58:54 AM More...

1